Agios Pharmaceuticals AGIO Available-for-Sale Debt Securities - Amortized Cost
Available-for-Sale Debt Securities - Amortized Cost at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's available-for-sale debt securities - amortized cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's available-for-sale debt securities - amortized cost?
- Agios Pharmaceuticals (AGIO) reported available-for-sale debt securities - amortized cost of $932.21M in Q1 2026.
- How has Agios Pharmaceuticals's available-for-sale debt securities - amortized cost changed year-over-year?
- Agios Pharmaceuticals's available-for-sale debt securities - amortized cost decreased by 30.7% year-over-year, from $1.35B to $932.21M.
- What is the long-term trend for Agios Pharmaceuticals's available-for-sale debt securities - amortized cost?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's available-for-sale debt securities - amortized cost has grown at a 14.6% compound annual growth rate (CAGR), from $543M to $1.07B.
- What does available-for-sale debt securities - amortized cost mean?
- This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.